| UniProt | <a href="https://www.
Parkin is an E3 ubiquitin ligase with unique domain architecture:
- N-terminal ubiquitin-like (Ubl) domain (1-76): Binds to proteasome, regulates activity
- RING0 (77-151): Unique to parkin
- RING1 (152-228): Coordinates E2 binding
- IBR (In-between-RING) (229-328): Flexible linker
- RING2 (329-410): Catalytic RING finger
- RING2: Contains active site Cys (431) for ubiquitin transfer
Mutations disrupt the structural arrangement, inactivating the ligase.
Parkin is essential for mitochondrial quality control:
- E3 ubiquitin ligase: Targets proteins for ubiquitination
- Mitophagy: With PINK1, ubiquitinates damaged mitochondria
- Mitochondrial dynamics: Regulates fission and fusion proteins
- Protein quality control: Degrades misfolded proteins
- Neuronal survival: Protects against oxidative stress
- Mutations: >200 pathogenic variants throughout the gene
- Pathology:
- Loss of E3 ligase activity
- Impaired mitophagy
- Accumulation of damaged mitochondria
- Progressive dopaminergic neuron loss
- Usually Lewy body-negative
- Heterozygous mutations may be risk factors
- Small molecule activators: In development
- Gene therapy: AAV-PRKN delivery
- Mitophagy enhancers: Upstream activators
-
Kitada T, et al. (1998). "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." Nature. PMID:9512135
-
Narendra D, et al. (2008). "Parkin is recruited selectively to impaired mitochondria." Curr Biol. PMID:18198282
-
Matsuda N, et al. (2010). "PINK1 stabilized by mitochondrial depolarization recruits Parkin." J Cell Biol. PMID:20133581
The study of Parkin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Kitada T, et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. PMID:9529217.
- 2 Shimura H, et al. (2000). Ubiquitination of a new form of alpha-synuclein by parkin from human brain. Science. PMID:10677402.
- 3 Zhang Y, et al. (2000). Parkin functions as an E2-dependent ubiquitin-protein ligase. Proc Natl Acad Sci USA. PMID:10944220.
- 4 Narendra D, et al. (2008). Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy. PMID:18938152.
- 5 Pickrell AM, et al. (2015). Endogenous Parkin Preserves Mitochondrial Function during Cellular Stress. Neuron. PMID:25611511.
-
- See: PRKN Gene - Gene encoding this protein
- See: Parkinson's disease - Disease context
- See: PINK1 Protein - Partner in mitophagy
- See: mitophagy - Cellular mechanism
Over 200 pathogenic mutations in the PRKN gene cause autosomal recessive juvenile Parkinson's disease:
- p.C253Y: Disrupts RING1 domain, impairs E2 binding
- p.T415N: Affects IBR domain, reduces activity
- p.G430D: Destabilizes RING2 domain
- p.DelEx4-5: Common deletion, removes critical exons
- p.Arg275Trp: One of most common point mutations
These mutations disrupt the E3 ligase activity, preventing mitophagy and leading to mitochondrial dysfunction.
Parkin collaborates with PINK1 in the mitochondrial quality control pathway:
- Activation: PINK1 phosphorylates ubiquitin and Parkin
- Ubiquitination: Parkin adds K27, K48, K63-linked chains
- Receptor recruitment: Autophagy receptors bind ubiquitin chains
- Autophagosome formation: LC3 conjugation facilitates engulfment
- Lysosomal fusion: Degradation of mitochondrial components
Parkin ubiquitinates numerous outer membrane proteins:
- Miro1/2: Mitochondrial Rho GTPases
- VDAC1: Voltage-dependent anion channel
- Mitofusins: Mitochondrial fusion proteins
- TOM complex: Translocase of outer membrane
- PRKN mutations cause 10-20% of juvenile PD cases
- Autosomal recessive inheritance
- Onset typically before age 40
- Excellent levodopa response
- May have slower progression
- Loss of dopaminergic neurons in substantia nigra
- Lewy bodies may be absent in PRKN-linked cases
- Mitochondrial complex I deficiency
- Widespread mitochondrial dysfunction
- Fibroblasts: Reduced Parkin expression
- Blood: Altered ubiquitin profiles
- CSF: Elevated mitochondrial DNA
- AAV-PARK2 delivery to striatum
- CRISPR-based gene correction
- Viral vector-mediated expression
- Parkin activators: Increase E3 ligase activity
- Protein-protein interaction disruptors: Prevent autoinhibition
- Phosphomimetics: Active Parkin analogs
- CoQ10 and analogs
- Mitochondrial-targeted antioxidants
- Autophagy enhancers
¶ Domain Analysis
- Ubl domain: Regulated, cleaved under stress
- RING0: Unique to Parkin, stabilizes structure
- RING1-IBR-RING2: Catalytic core
- Active site Cys431: Essential for ubiquitin transfer
- Auto-inhibited state: Ubl domain blocks active site
- Activated state: Phosphorylation induces conformational shift
- Active conformation: Substrate access enabled
- PINK1: Kinase that activates Parkin
- E2 enzymes: UbcH7, UbcH8, Ube2L3
- Autophagy receptors: p62, OPTN, NDP52
- Proteasome subunits: 19S regulatory particle
- NF-κB signaling: Parkin regulates inflammation
- Apoptosis pathways: Anti-apoptotic functions
- Mitochondrial dynamics: Fusion/fission regulation
- Knockout mice: Mild phenotype, age-related changes
- Transgenic models: Variable phenotypes
- Humanized models: Better recapitulation
- parkin RNAi: Robust dopaminergic neuron loss
- Mitochondrial defects: Energy depletion
- Behavioral phenotypes: Climbing deficits
- Phospho-ubiquitin levels
- Mitochondrial function assays
- Patient-derived iPSC characterization
- High-throughput screening for activators
- Structure-based design
- Phenotypic screening in patient cells
|
|---|